Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00471146
Status:
COMPLETED
Last Update Posted:
2012-07-16
First Post:
2007-05-07
Brief Title:
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Randomized Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced Unresectable Or Metastatic Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether investigational study drug AG-013736 and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer
Detailed Description:
This study was prematurely discontinued for futility on 23 January 2009 based on a planned interim analysis by an independent Data Safety Monitoring Board DSMB that found no evidence of improvement in the primary endpoint survival in patients treated with axitinib and gemcitabine compared to gemcitabine alone Enrollment on this study has been discontinued
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None